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Introduction
Fragile X Syndrome (FXS) is a neurodevelopmental disorder which affects intellectual, social and physical development of both men (1 in 4000) and women (1 in 8000) 1 . Individuals with FXS experience intellectual disability and symptoms of autism 2, 3 as well as altered sensory sensitivity [4] [5] [6] , repetitive behaviours 7 , social communication deficits 8 , and increased anxiety 2 . FXS is caused by CGG repeat expansion in the 5' untranslated region of the Fragile X mental retardation 1 gene (FMR1) 9 . Repeat expansion in excess of 200 copies results in epigenetic silencing of FMR1 and loss of Fragile X mental retardation protein (FMRP).
FMRP is an RNA-binding protein 10 which negatively regulates protein translation and is required for normal neural development, as it binds to transcripts of proteins involved in synaptic function 11 . Other molecular signaling pathways are also affected in FXS, such as mTOR signalling 12 , a crucial factor for protein synthesis and cellular growth 13 . Treatment options in FXS are currently limited, and have until recently focused on specific domains of symptom relief (predominantly anxiety, attention deficit, and hyperactivity) 14, 15 . Thus, new treatment alternatives informed by increased understanding of FXS neurobiology are urgently required.
As a tool for understanding FXS, a germline Fmr1 knockout (KO) mouse model was developed 16 . This rodent model mimics the complete loss of FMRP which occurs in individuals with the full mutation (>200 repeats), and can be used for evaluation of novel therapeutic strategies. Fmr1 KO mice display a range of altered behaviours compared to control mice, some of which are consistent with the clinical picture for FXS or autism (for review see 17 and 18 ). Fmr1 KO mice display less preference for social novelty than wild type-like mice 19 , consistent with social deficits in FXS 8 and are consistently hyperactive [20] [21] [22] [23] [24] . Spatial working memory abnormalities have been described 16, [25] [26] [27] , but not consistently 28, 29 . Similarly, studies on the anxiety-related phenotype of this mouse model report both Recently, the endocannabinoid system has become a target of preclinical research into FXS 33, 34 as FMRP, which is diminished in FXS, facilitates the production of the endocannabinoid 2-arachidonoylglycerol (2-AG) 35 . In line with this, Fmr1 KO mice exhibit lower levels of 2-AG than control mice 35 and dimished retrograde 2-AG signaling in the hippocampus 36 . The phosphatidylinositol-3-kinase (PI3K)-protein kinase B (Akt)-mTOR-p70S6 kinase (p70S6K) signalling pathway 37, 38 is a downstream target of the endocannabinoid system and is dysregulated in Fmr1 KO mice 12 . The non-psychoactive phytocannabinoid cannabidiol (CBD) may have benefits for FXS patients based on its capacity to modulate FXScompromised endocannabinoid signalling. CBD may attenuate the pathophysiology of the disease by indirectly increasing the concentration of the two main endocannabinoids, 2-AG and N-arachidonoylethanolamine (AEA, anandamide) [39] [40] [41] . In the mouse hippocampus, levels of anandamide but not 2-AG increase after 14 day treatment with 30mg/kg CBD 42 .
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Furthermore, CBD has neuroprotective effects 43, 44 and can increase adult hippocampal neurogenesis 45 . On a behavioural level, CBD has been found to carry anti-anxiety and antipsychotic-like properties [46] [47] [48] and improve social impairments 49 , suggesting therapeutic potential for FXS. Indeed, CBD is a promising new therapy for Dravet and Lennox-Gastaut syndromes, which cause seizures and developmental delay 50 . Importantly, the ability of CBD to reverse FXS-related behavioural abnormalities of Fmr1 KO mice has not previously been evaluated.
The current study assessed the ability of CBD treatment to rescue behavioural deficits of male Fmr1 KO mice. The open field test, elevated plus maze, passive avoidance test, the
continuous Y maze, and the social preference test were performed to index locomotion, anxiety-related behaviour, social behaviours and working memory respectively, and to evaluate the potentially therapeutic-like effects of CBD on Fmr1 KO-related deficits. Plasma and brain concentrations of CBD were also analysed to check for potential differences in CBD pharmacokinetics across genotypes.
Materials and methods

Animals
Fmr1 knockout mice 16 A C C E P T E D M A N U S C R I P T 
Behavioural Phenotyping
Starting at 5 months of age (±1 week; after 3 weeks of habituation to the facilities), mice were tested in a battery of behavioural tests. All tests were conducted during the first 5 h of the light phase to minimise effects of the circadian rhythm on the performance of test mice.
The test order was as follows: open field, elevated plus maze, spontaneous alternation in the Y maze, social preference, and passive avoidance tasks. Equipment and apparatus were cleaned between trials using 70% ethanol except where specified (i.e. open field testing).
Open field (OF):
The OF mimics the natural conflict in mice between the tendency to
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Elevated plus maze (EPM):
The EPM assesses the natural conflict between the tendency of mice to explore a novel environment and avoidance of a brightly lit, elevated and open area 60 . The grey plus maze was "+" shaped [for details of apparatus see 61 . Mice were placed at the centre of the + (faced towards an enclosed arm) and were allowed to explore the maze for 5 min. 
Continuous spontaneous alternation in the Y-maze (SA):
The Y-maze SA test measures the willingness of mice to explore novel environments. Rodents typically prefer to investigate a new arm of a maze rather than returning to one that was previously visited 62 . The Y-maze used in our laboratory consisted of three grey acrylic arms (10 cm x 30 cm x 17 cm) placed at 120° with respect to each other. Around the arms were distal cues. Animals were placed into
the centre of the Y-maze and allowed to freely explore the environment for 10 min. Order of entries into the three different arms (A, B, or C) was recorded and successful arm entry triplets (i.e. ABC, ACB, BCA, BAC, CAB, CBA) calculated (maximal number of correct triplets = total number of arm entries -2) 52 . Percentage of correct arm entries was calculated.
AnyMaze TM software was used to track the animal's movement in the maze: an arm entry was scored whenever an animal entered the 2 nd half of the arm with more than 60% of its body length.
Passive avoidance:
In this basic hippocampus-dependent learning test, the avoidance of a naturally less aversive dark compartment after it is paired with an electrical foot shock indicates the retention of this memory 63 . In the training session, CBD was administered then 30 min later mice were placed in an illuminated compartment (illumination: 25 lx; 25 x 15 x 25 cm; model H10-11R-TC, Coulbourn Instruments, USA). After 10 s, the door to a dark chamber was opened and the latency to enter was measured manually. Once the mouse had entered the dark chamber (illumination: 1 lx; 25 x 12 x 25 cm), the door was closed and a single foot shock (0.4 mA for 2 s) was delivered. Mice were kept in the dark chamber for another 60 s to facilitate the formation of an association between the dark chamber and the foot shock. In the retention session 24 h later, mice were placed in the light compartment and the latency to enter the dark chamber was measured manually (cut-off time: 300 s) as published previously from our laboratory 64 . Latency was compared between training and test sessions-increased entry latency on the second day indicates memory of the aversive stimulus.
Social preference test (SPT):
The SPT was used to assess sociability and social recognition memory 65 and performed as described in our earlier studies 66, 67 . Test animals
were isolated for an hour prior to the start of testing. During the habituation trial, mice were allowed to explore a three-chamber apparatus, consisting of a centre chamber ( 
Analysis of CBD Concentrations in Plasma and Brain
At least one week after the completion of the behavioural testing (see 2. 
Statistical Analysis
Two-way analysis of variance (ANOVA) was performed to investigate main effects of 'genotype' and 'CBD dose' and possible interactions. Repeated measures (RM) three-way ANOVAs were used to investigate total distance travelled across time, i.e. '5-min block'
(OF), 'latency' (training session vs test session; PA), and 'chamber' (SPT) and 'time' (CBD concentrations) as published previously 67 . In line with Rothman and Perneger 68, 69 , the data were not adjusted for multiple comparisons and were interpreted as such in the discussion.
Paired t-tests were performed to investigate the preference of mice in the SPT test against chance levels (i.e. 50%). Finally, for analysis of CBD levels, missing values (i.e. samples below the limit of detection of 0.5ng/ml) were assigned a value of 0.49. Three-way ANOVAs were then employed to determine relationships between 'genotype', 'CBD dose' and 'time' 
Results
Locomotion and exploration
Fmr1 KO mice exhibited a hyperlocomotive and hyperexplorative phenotype in the 30 min OF test (Fig. 1A-B Fig 2D) . Table 2 ). Paired t-tests showed that only control mice treated with 20 mg CBD displayed levels of spontaneous alternation significantly above the chance level of 50% ( or 'CBD' was detected; both p > .05], suggesting that all mice had learned equally the association between the foot shock and the dark compartment and CBD treatment did not alter this association (Fig. 3 ). 
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Social Behaviours
Mice across all experimental groups demonstrated a significant preference for exploring a 
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CBD concentrations
In both Fmr1 KO and WT mice, CBD concentrations in the brain and plasma were highly (Table 3 ).
In plasma, CBD levels did differ subtly between genotypes [F(1,60) = 4.7, p = .03].
Interestingly, this effect was driven by differences at 20 mg CBD in brains collected 90 min post administration (three-way 'genotype' x 'CBD' x 'time' interaction, p < .005) where CBD levels were lower in Fmr1 KO mice than WT mice ( Table 3) interaction (p < .001; Table 3 ). Collapsed across genotypes, a strong correlation between plasma and brain concentrations of CBD was observed for both 5 mg CBD (r = .870, p <
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.001) and 20 mg CBD (r = .956, p < .001). 
Discussion
Here we present the effects of acute CBD treatment on an established genetic mouse model for FXS. The Fmr1 KO mice in our study displayed a phenotype which was broadly consistent with the literature. Compared to WT mice, Fmr1 KO mice were hyperactive, hyperexplorative and displayed fewer anxiety-like behaviours. This is consistent with the majority of studies using these tests 20-22, 26, 30 . As in this study, other studies have failed to observe social behaviour deficits 30, 70 or spatial memory deficits 28, 29 . However it is important to note that the Fmr1 KO behavioural phenotype is variable. There have been differing findings from those reported here for tasks which assess locomotor activity 26, 71 ,
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anxiety 27, 31 , social behaviour 21, 26, 70, 72 and spatial memory 16, 21, [25] [26] [27] . This includes work by a subset of the current authors in a different facility 26 .
In this context, acute CBD had no impact on locomotion or anxiety-related parameters of the OF. However, in the EPM test, 20mg/kg CBD (but not 5mg/kg CBD) decreased the anxiety response of all mice tested. CBD treatment did not affect cognitive performance of animals in the spontaneous alternation task and the passive avoidance task.
To assess pharmacokinetics we administered CBD (5 or 20mg/kg) to Fmr1 KO and WT mice, then sacrificed them 30 or 90 min post-administration and measured CBD in brain and plasma of each animal. Although CBD levels in brain were equivalent in both genotypes at both timepoints, and in plasma were equivalent at 30 min post-administration, CBD levels were lower in plasma in Fmr1 KO mice at 90 min post-administration. This suggests that
Fmr1 KO mice may clear CBD more rapidly than WT mice. However, there was no evidence from our behavioural tests that CBD had differential pharmacodynamic effects in Fmr1 KO and WT mice (all genotype x CBD interactions were non-significant).
Male mice only were used for initial characterisation of effects of CBD, because males with FXS typicaly have greater severity of symptoms and male Fmr1 KO mice have been more exhaustively characterised in the literature. However, use of homozygous female Fmr1 KO mice in future experiments would be beneficial.
Individuals affected by FXS have been found to be hyperactive 73, 74 . Similarly, Fmr1 KO tested in our study exhibited a hyper-locomotive and hyper-explorative phenotype in the OF, consistent with previous studies [20] [21] [22] . This OF phenotype was evident in both the vehicletreated as well as the CBD-treated cohorts. The lack of locomotor effects of CBD in the current study are consistent with previous data from our lab indicating that neither acute nor chronic CBD treatment (ranging from 1-50 mg/kg bodyweight) induces sedative-like effects in male C57BL/6J mice 52 or reverses the hyperactive phenotype of an established genetic
20 mouse model for schizophrenia 49 . However, it is important to note the discrepant findings in this research area, as CBD has been shown to be effective in ameliorating the 'psychotic-like' stimulating effect of acute amphetamine on locomotion 52 20, 23, 24 in Fmr1 knockout models as seen in our study. These inconsistencies across research studies appear to be independent of ]
. The effect of acute CBD treatment was similar for all mice and the genotype differences were not affected by the treatment, suggesting that FMRP is not required for anxiolytic-like effects of acute CBD.
Pharmacological blockade of the cannabinoid receptor 2 (CB 2 ) (but not the CB 1 receptor) has been effective in normalizing the anxiety behaviour of Fmr1-deficient mice 33 . However, since CBD has low affinity and/or weak indirect action at CB 1 and CB 2 receptors 40 it is more likely that CBD decreases anxiety via another mechanism, such as binding to the 5-HT 1A receptor 56, 77, 78 . Given that individuals with FXS experience increased anxiety 32, 79 but we (and others) find decreased anxiety in Fmr1 KO mice, the therapeutic value of CBD's antianxiolytic effect in FXS requires clarification in future studies.
Most people with FXS are affected by mild to severe intellectual impairments 32 . We did not identify a deficit of fear-associated memory (i.e. passive avoidance) in Fmr1 KO mice in this study-all mice displayed increased latencies to enter the dark chamber after receiving a foot shock. We also did not observe a difference between Fmr1 KO mice and controls in spatial working memory (i.e. spontaneous alternation). This result should be interpreted with caution since only WT mice treated with 20mg/kg CBD showed levels of alternation significantly above chance (50%). Similar to the anxiety phenotype, the literature provides an inconsistent picture of the cognitive phenotype of Fmr1 KO mice (reviewed in 18 ) although knockout mice can show impaired spatial memory when tested in the passive avoidance 16, 20, 34, 71, 75 , T maze 21, 26 and Y maze 27 paradigms. In our study, CBD had no impact on spatial working memory (spontaneous alternation) and fear-associated spatial memory (passive avoidance). Other studies in our laboratory have found beneficial effects of CBD in cognitive domains, as deficits in recognition memory of a transgenic mouse model for Alzheimer's disease were rescued and prevented after chronic CBD treatment 51, 67 . In line with the latter finding, two studies explored the effects of modulating the endocannabinoid system on passive avoidance behaviour in Fmr1 KO mice. Blocking the CB 1 (but not the CB 2 ) receptor pharmacologically (acutely as well as chronically) using rimonabant ameliorated impairments in recognition memory 33 . In another study, increasing the endocannabinoid tone using propofol or URB-597, both inhibitors of fatty acid amide hydrolase activity (FAAH: catabolic enzyme for endocannabinoids), post training resulted in an improved passive avoidance performance of Fmr1 KO mice without any effect on control animals 34 . However, the experimental protocol of Qin and colleagues (2015) was substantially different from our study, as they used habituation trials, two training days, and a post-training administration regime.
Although all mice (regardless of genotype and treatment) developed the preference to explore a mouse over an empty chamber, a significant preference for social novelty was absent in A C C E P T E D M A N U S C R I P T We would like to thank Jerry Tanda for critical comments on the manuscript and Adam
Bryans for taking care of our test mice at NeuRA.
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A C C E P T E D M A N U S C R I P T 32 Highlights -Acute cannabidiol (CBD) decreased anxiety-related behaviours in both Fmr1 knockout mice and wildtype controls in the elevated plus maze -Fmr1 KO mice were hyperlocomotive, hyperexplorative, showed fewer anxiety-related behaviours and habituated more slowly to a novel environment than controls -Acute CBD had no impact on locomotion, spatial working memory or fear-associated memory in Fmr1 knockout mice or controls.
